Cargando…
Case Report: Kaposiform hemangioendothelioma with PIK3CA mutation successfully treated with sirolimus
Kaposiform hemangioendothelioma (KHE) is an extremely rare, locally aggressive vascular neoplasm. The etiopathogenesis of KHE is still poorly understood. In the present study, we found a new mutation in KHE (c.685delA, p.Thr229fs). The KHE patient with the PIK3CA mutation showed complete regression...
Autores principales: | Wang, Zuopeng, Yan, Hanlei, Ma, Yangyang, Yao, Wei, Zheng, Shan, Li, Kai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10235594/ https://www.ncbi.nlm.nih.gov/pubmed/37274236 http://dx.doi.org/10.3389/fonc.2023.1132702 |
Ejemplares similares
-
Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
por: Triana, Paloma Junco, et al.
Publicado: (2017) -
Sirolimus for treatment of kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon
por: Alaqeel, Alaa M., et al.
Publicado: (2016) -
Sirolimus for Kaposiform Hemangioendothelioma and Kasabach-Merritt Phenomenon in a Neonate
por: Cabrera, Trevor B., et al.
Publicado: (2020) -
Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma: A retrospective study
por: Wang, Dongdong, et al.
Publicado: (2019) -
Successful Management of Kaposiform Hemangioendothelioma with Long-Term Sirolimus Treatment: a Case Report and Review of the Literature
por: Chinello, Matteo, et al.
Publicado: (2018)